Bryan M. Marra | People | Arnold & Porter

Bryan Marra counsels clients at successfully navigating government merger reviews and Second Request investigations. He has represented clients in Department of Justice and FTC merger investigations in a wide range of industries, including media, telecommunications, consumer products and the hospital sector. He has led the response to a number of complex investigations and has particular expertise in managing the e-discovery process, including the use of technology-assisted review, and other techniques to efficiently manage and streamline the compliance process.

In addition, Bryan has significant experience in pharmaceutical antitrust matters, representing clients in litigation and government investigations involving Hatch-Waxman patent settlements and lifecycle management practices. Before joining the firm, Bryan also served as a Legal Fellow on the Senate Judiciary Committee, Antitrust Subcommittee.

Focus Areas

Experience

Pfizer in its $43 billion acquisition of Seagen Inc., a world-leader in antibody-drug conjugates (ADCs).
AT&T Inc. in its successful $85.4 billion stock-and-cash acquisition of Time Warner Inc. After a Second Request and the first vertical merger trial/appeal in decades, the transaction was approved with no finding of liability.
General Electric in the $11 billion merger of Wabtec and GE Transportation. After a Second Request investigation that focused on potential vertical theories, the transaction was permitted to proceed without any remedy.
Monsanto in connection with its $66 billion acquisition by Bayer, which closed after a 20-month DOJ investigation leading to what the DOJ characterized as "the largest negotiated merger divestiture ever required by the United States." The transaction was reviewed and approved by antitrust enforcers in the U.S., the EU, and almost 30 other jurisdictions.
Komatsu Ltd. in connection with its approximately $2.9 billion acquisition of high-productivity mining equipment company, Joy Global.

Emanuel Medical Center in its sale to Tenet Healthcare; transaction closed after compliance with FTC second request.
General Electric Co. in the sale of its NBC Universal majority stake to Comcast; managed compliance effort in response to DOJ second request and FCC information requests.
PepsiCo in its $7.8 billion acquisition of its two largest bottlers, Pepsi Bottling Group, Inc., and PepsiAmericas; transaction permitted to close without second request after negotiating and entering consent decree with FTC.
Boston Scientific in its $27 billion acquisition of Guidant, creating one of the largest medical technology companies in the world; counseled Boston Scientific in obtaining clearance in the EU and multiple other international jurisdictions.
NBC in its $5.2 billion acquisition of Vivendi Universal Entertainment, creating one of the world's largest media and entertainment companies.